MageA1-TCR gene therapy - MediGene
Latest Information Update: 17 Mar 2017
At a glance
- Originator MediGene AG
- Mechanism of Action Gene modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 17 Mar 2017 MediGene plans a phase I/II trial for an undisclosed indication in the second half of 2018 (MediGene pipeline, March 2017)
- 17 Mar 2017 MediGene plans a clinical trial for an undisclosed indication in the second half of 2017 (MediGene pipeline, March 2017)
- 16 Nov 2016 MediGene, Max Delbruck Centre plan a phase I trial for Multiple myeloma (MediGene website, November 2016)